Questions on the CC focused on whether STOP-HE can still serve as one of the two required pivotal studies for FDA approval of the IV formulation of OCR-002 as a treatment for acute HE. The company did not give a clear answer, but missing the primary endpoint would seem to make this unlikely.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.